| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911260 | Lung Cancer | 2012 | 6 Pages |
Abstract
In previously treated, unselected, advanced NSCLC patients, the addition of enzastaurin to erlotinib did not improve PFS, response, or OS compared with historical data of single-agent erlotinib, but was well tolerated.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Christelle Clément-Duchêne, Ronald B. Natale, Thierry Jahan, Yelena Krupitskaya, Raymond Osarogiagbon, Rachel E. Sanborn, Eric D. Bernstein, Arkadiusz Z. Dudek, Jane E. Latz, Peipei Shi, Heather A. Wakelee,